Natco Pharma is focusing on filing of cancer treatment drugs in China, the world’s second largest pharmaceutical market, as part of its strategy to diversify business in various emerging markets amid headwinds in the US.
Even as the drug industry faces a host of growth-stunting challenges, U.S. pharma compernies cut down fewer numbers of employees this year than same period in 2016, according to the analysis.